Cancers, Journal Year: 2025, Volume and Issue: 17(2), P. 268 - 268
Published: Jan. 15, 2025
Pathway inhibitors targeting Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) have dramatically changed the treatment landscape for both treatment-naïve relapsed/refractory chronic lymphocytic leukemia (CLL). However, with increased utilization, a growing number of patients will experience progressive disease on agents. This subgroup “double refractory” has limited options poor prognosis. Chimeric antigen receptor (CAR)-T cells transformed malignancies. Although earliest success CAR-T cell therapy was in CLL, clinical application this modality lagged until recent approval first product CLL. In review, we describe current upfront subsequent therapies unmet need novel agents highlighted by burgeoning role challenges therapy.
Language: Английский